DaVita Inc. $DVA Shares Sold by Cannell & Spears LLC

Cannell & Spears LLC cut its position in shares of DaVita Inc. (NYSE:DVA) by 44.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 14,720 shares of the company’s stock after selling 12,000 shares during the period. Cannell & Spears LLC’s holdings in DaVita were worth $2,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Kesler Norman & Wride LLC raised its holdings in shares of DaVita by 0.8% during the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after purchasing an additional 55 shares during the period. Gen Wealth Partners Inc boosted its holdings in shares of DaVita by 10.0% in the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after buying an additional 80 shares during the period. NewEdge Advisors LLC grew its position in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the last quarter. Orion Porfolio Solutions LLC raised its stake in DaVita by 4.4% during the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock worth $268,000 after acquiring an additional 99 shares during the period. Finally, Root Financial Partners LLC lifted its holdings in DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on DVA. TD Cowen lifted their target price on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. Truist Financial raised their price target on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Barclays boosted their price objective on DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and increased their target price for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. Finally, Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DaVita presently has a consensus rating of “Hold” and an average price target of $216.50.

DaVita Stock Performance

Shares of DVA stock opened at $235.46 on Friday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $239.64. The stock has a fifty day moving average of $213.62 and a two-hundred day moving average of $168.71. The firm has a market capitalization of $15.12 billion, a PE ratio of 21.84, a price-to-earnings-growth ratio of 0.77 and a beta of 0.88.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts predict that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.90% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.